Gottlieb op-ed: Manufacturers need to ramp up production of antibodies as 'Covid insurance policy'

Gottlieb op-ed: Manufacturers need to ramp up production of antibodies as 'Covid insurance policy'

Source: 
Endpoints
snippet: 

After Pfizer and BioNTech scored the FDA’s emergency use authorization for their mRNA-based Covid-19 shot late last week, hopes are high that one or more vaccines could turn the tide on the pandemic. But vaccines will take time to get into arms, and a former FDA head is calling on drugmakers to double down on making antibody therapies as a “Covid insurance policy” in the meantime.